<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371474</url>
  </required_header>
  <id_info>
    <org_study_id>112308</org_study_id>
    <nct_id>NCT01371474</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)</brief_title>
  <official_title>Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this survey was to understand the safety and efficacy of PAXIL tablets
      (&quot;PAXIL&quot;, hereinafter) when it was started at 20 mg/day in subjects with depression or in a
      depressed state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events in Japanese subjects treated with paroxetine tablet based on prescribing information under the conditions of general clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy evaluation based on overall improvement</measure>
    <time_frame>12 weeks</time_frame>
    <description>The investigator compared the general condition over 1 week before each clinical visit with that over 1 week before the start of treatment with PAXIL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy evaluation based on severity by symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>At every clinical visit, the investigator rated each of the specified symptoms including depressed mood, loss of interests/concerns, anxiety, lack of motivation, physical symptoms, and sleep disorders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy evaluation based on Beck Depression Inventory- Second Edition (BDI-II)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The investigator asked each subject to fill out the self-administered form of BDI-II at every clinical visit (recommended clinical visit schedule: 1, 2, 4, 8, and 12 weeks after the start of treatment).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1483</enrollment>
  <condition>Panic Disorder</condition>
  <arm_group>
    <arm_group_label>Patients prescribed PAXIL</arm_group_label>
    <description>Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <arm_group_label>Patients prescribed PAXIL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japanese subjects with depression or in a depressed state who are considered appropriate to
        prescribe paroxetine tablet starting at 20mg/day according to the prescribing information
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with depression or in a depressed state

          -  Patients who start taking paroxetine at 20mg a day

        Exclusion Criteria:

          -  Patients who have been treated with paroxetine prior to this investigation

          -  Patients with hypersensitivity to paroxetine

          -  Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping
             treatment with MAOIs

          -  Concomitant use in patients taking pimozide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

